{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T09:43:15Z","timestamp":1769420595576,"version":"3.49.0"},"reference-count":35,"publisher":"Georg Thieme Verlag KG","issue":"01","license":[{"start":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T00:00:00Z","timestamp":1769299200000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq Neuropsiquiatr"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Parkinson's disease (PD) is a progressive neurodegenerative disorder associated with substantial disability, morbidity, and mortality. Timely diagnosis and treatment are essential to mitigate its impact. Despite its burden, real-world data on PD in Brazil remain limited.<\/jats:p>\n                  <jats:p>To describe the demographic and clinical profile of individuals with PD treated in the Brazilian public healthcare system and to evaluate patterns of treatment and healthcare resource utilization (HCRU).<\/jats:p>\n                  <jats:p>The present observational, retrospective, longitudinal study analyzed data from the Brazilian public healthcare system (Sistema \u00danico de Sa\u00fade, SUS, in Portuguese) between January 2013 and December 2022. Patients aged \u2265 20 years with at least 2 core procedures coded for PD (ICD-10 G20) were included. Inpatient and outpatient datasets were analyzed separately.<\/jats:p>\n                  <jats:p>A total of 53,674 PD patients were identified. The mean age at diagnosis was 65.4 years, with a slight male predominance (53.0%). Most patients (47.0%) had more than 6 outpatient visits, and 44.4% had 1 or 2 hospitalizations. The most frequent procedures were PD treatment (inpatient) and physical therapy (outpatient). The most used medications were pramipexole (45.6%), amantadine (26.0%), and entacapone (17.1%).<\/jats:p>\n                  <jats:p>The present study provides valuable insights into the demographic and clinical profile of PD patients in Brazil, highlighting frequent procedures and treatment patterns. A key limitation is the non-capture of basic PD medications, such as levodopa, which are often dispensed outside the analyzed datasets. These findings underscore the need for improved data integration and access to comprehensive PD care within the public health system.<\/jats:p>","DOI":"10.1055\/s-0045-1814375","type":"journal-article","created":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T23:30:22Z","timestamp":1769383822000},"page":"001-011","source":"Crossref","is-referenced-by-count":0,"title":["Demographics, treatment patterns, and healthcare resource utilization in Parkinson's disease: a real-world data study using a claims database"],"prefix":"10.1055","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9929-1148","authenticated-orcid":false,"given":"Alexandre Battaglini","family":"Chehin","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago IL, United States of America."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1386-5794","authenticated-orcid":false,"given":"Luciana Rahal","family":"Abrah\u00e3o","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago IL, United States of America."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1402-2952","authenticated-orcid":false,"given":"Marcos Augusto Mira","family":"Fuga","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago IL, United States of America."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9111-1360","authenticated-orcid":false,"given":"Ana Beatriz Machado de","family":"Almeida","sequence":"additional","affiliation":[{"name":"IQVIA Brasil, S\u00e3o Paulo SP, Brazil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3937-0258","authenticated-orcid":false,"given":"Angelica Carreira dos","family":"Santos","sequence":"additional","affiliation":[{"name":"IQVIA Brasil, S\u00e3o Paulo SP, Brazil."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3565-5328","authenticated-orcid":false,"given":"Jacy Bezerra","family":"Parmera","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Faculdade de Medicina, Hospital das Cl\u00ednicas, Departamento de Neurologia, S\u00e3o Paulo SP, Brazil."},{"name":"Hospital Israelita Albert Einstein, S\u00e3o Paulo SP, Brazil."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2026,1,25]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease","volume":"3","author":"W Poewe","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"08","key":"ref2","first-page":"504","article-title":"Parkinson's Disease and Its Management: Part 1: Disease Entity, Risk Factors, Pathophysiology, Clinical Presentation, and Diagnosis","volume":"40","author":"G DeMaagd","year":"2015","journal-title":"P&T"},{"issue":"11","key":"ref3","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","article-title":"Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"17","author":"GBD 2016 Parkinson's Disease Collaborators","year":"2018","journal-title":"Lancet Neurol"},{"issue":"11","key":"ref4","first-page":"679","article-title":"Parkinson Disease","volume":"102","author":"A D Halli-Tierney","year":"2020","journal-title":"Am Fam Physician"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"480260","DOI":"10.4061\/2010\/480260","article-title":"Treatment of advanced Parkinson's disease","volume":"2010","author":"S Varanese","year":"2011","journal-title":"Parkinsons Dis"},{"issue":"S 01","key":"ref7","first-page":"S3","article-title":"[Limits of conventional oral and transdermal medication in Parkinson's disease]","volume":"55","author":"P J Garc\u00eda-Ruiz","year":"2012","journal-title":"Rev Neurol"},{"key":"ref8","first-page":"S59","article-title":"Parkinson's disease\u2013Part 3: Neuropsychiatric symptoms","volume":"14","author":"D Weintraub","year":"2008","journal-title":"Am J Manag Care"},{"issue":"08","key":"ref9","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/nrneurol.2012.126","article-title":"Late-stage Parkinson disease","volume":"8","author":"M Coelho","year":"2012","journal-title":"Nat Rev Neurol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3389\/fneur.2018.00156","article-title":"Diagnostic Criteria for Parkinson's Disease: From James Parkinson to the Concept of Prodromal Disease","volume":"9","author":"L Marsili","year":"2018","journal-title":"Front Neurol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13550-015-0087-1","article-title":"The diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with Parkinson's disease or clinically uncertain parkinsonism: a systematic review","volume":"5","author":"S R Suwijn","year":"2015","journal-title":"EJNMMI Res"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00702-021-02452-7","article-title":"Dopamine transporter (DAT) imaging in Parkinson's disease and related disorders","volume":"129","author":"T Br\u00fccke","year":"2022","journal-title":"J Neural Transm (Vienna)"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.nicl.2017.07.011","article-title":"Diffusion tensor imaging in Parkinson's disease: Review and meta-analysis","volume":"16","author":"C Atkinson-Clement","year":"2017","journal-title":"Neuroimage Clin"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"502","DOI":"10.3389\/fneur.2020.00502","article-title":"Patient-Centric Care for Parkinson's Disease: From Hospital to the Community","volume":"11","author":"Y M Aye","year":"2020","journal-title":"Front Neurol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"222","DOI":"10.20517\/2347-8659.2020.58","article-title":"A review on Parkinson's disease treatment","volume":"8","author":"T Lee","year":"2021","journal-title":"Neuroimmunol Neuroinflamm"},{"issue":"06","key":"ref16","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s11910-024-01339-w","article-title":"Epidemiology of Parkinson's Disease: An Update","volume":"24","author":"J R Deliz","year":"2024","journal-title":"Curr Neurol Neurosci Rep"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.33448\/rsd-v11i1.24535","article-title":"Parkinson's Disease: Epidemiological pattern of hospital admission","volume":"11","author":"G F Santos","year":"2022","journal-title":"Res, Soc Dev"},{"issue":"137","key":"ref18","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1590\/0103-1104202313714I","article-title":"Hospitalization and mortality from Parkinson's Disease in Brazil from 2008 to 2020","volume":"47","author":"P RO Vasconcellos","year":"2023","journal-title":"Sa\u00fade Debate"},{"issue":"07","key":"ref19","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1590\/0004-282X-anp-2020-0409","article-title":"Genetics of Parkinson's disease in Brazil: a systematic review of monogenic forms","volume":"79","author":"B L Santos-Lobato","year":"2021","journal-title":"Arq Neuro-Psiquiatr"},{"issue":"04","key":"ref20","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1590\/S1413-81232006000400019","article-title":"Desigualdades geogr\u00e1ficas e sociais no acesso aos servi\u00e7os de sa\u00fade no Brasil: 1998 e 2003","volume":"11","author":"C Travassos","year":"2006","journal-title":"Cien Saude Colet"},{"key":"ref21","volume-title":"Demografia m\u00e9dica no Brasil 2020","author":"Conselho Federal de Medicina (CFM)","year":"2020"},{"key":"ref22","first-page":"5","article-title":"Access to health services in Brazil: inequalities and associated factors","volume":"55","author":"A CQ Barbosa","year":"2021","journal-title":"Rev Saude Publica"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s10389-024-02308-w","article-title":"Economic burden of Parkinson's disease and research trends: a bibliometric analysis","volume":"\u2022\u2022\u2022","author":"M Cunha","year":"2024","journal-title":"Journal of Public Health"},{"issue":"11","key":"ref24","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1007\/s00702-022-02484-7","article-title":"Best practice approaches to outpatient management of people living with Parkinson's disease during the COVID-19 pandemic","volume":"129","author":"A F Demleitner","year":"2022","journal-title":"J Neural Transm (Vienna)"},{"issue":"01","key":"ref25","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s42466-024-00325-4","article-title":"Diagnosis and treatment of Parkinson's disease (guideline of the German Society for Neurology)","volume":"6","author":"G H\u00f6glinger","year":"2024","journal-title":"Neurol Res Pract"},{"issue":"04","key":"ref26","doi-asserted-by":"publisher","first-page":"pzab302","DOI":"10.1093\/ptj\/pzab302","article-title":"Physical Therapist Management of Parkinson Disease: A Clinical Practice Guideline From the American Physical Therapy Association","volume":"102","author":"J A Osborne","year":"2022","journal-title":"Phys Ther"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1431079","DOI":"10.3389\/fnmol.2024.1431079","article-title":"Novel strategies in Parkinson's disease treatment: a review","volume":"17","author":"C L Mitchell","year":"2024","journal-title":"Front Mol Neurosci"},{"issue":"36","key":"ref28","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.15585\/mmwr.mm6936a4","article-title":"Delay or Avoidance of Medical Care Because of COVID-19\u2013Related Concerns\u2014United States, June 2020","volume":"69","author":"M\u00c9 Czeisler","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"02","key":"ref29","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3233\/JPD-202038","article-title":"The Impact of the COVID-19 Pandemic on Parkinson's Disease: Hidden Sorrows and Emerging Opportunities","volume":"10","author":"R C Helmich","year":"2020","journal-title":"J Parkinsons Dis"},{"issue":"05","key":"ref30","first-page":"454","article-title":"The impact of the COVID-19 pandemic on people with Parkinson's disease: a Brazilian perspective","volume":"79","author":"A G Silva","year":"2021","journal-title":"Arq Neuro-Psiquiatr"},{"issue":"03","key":"ref31","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1590\/0004-282X-ANP-2021-0219","article-title":"Guidelines for Parkinson's disease treatment: consensus from the Movement Disorders Scientific Department of the Brazilian Academy of Neurology - motor symptoms","volume":"80","author":"R A Saba","year":"2022","journal-title":"Arq Neuro-Psiquiatr"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/S1471-1931(00)00030-600030-6","article-title":"Continuous dopamine-receptor stimulation in early Parkinson's disease","volume":"23","author":"W Olanow","year":"2000","journal-title":"Trends Neurosci"},{"issue":"08","key":"ref33","doi-asserted-by":"publisher","first-page":"717","DOI":"10.3390\/ph14080717","article-title":"Current Therapies in Clinical Trials of Parkinson's Disease: A 2021 Update","volume":"14","author":"E M Prasad","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"issue":"06","key":"ref34","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1177\/1756285609339382","article-title":"Deep brain stimulation in Parkinson's disease","volume":"2","author":"S J Groiss","year":"2009","journal-title":"Ther Adv Neurol Disord"},{"issue":"02","key":"ref35","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/archneurol.2010.260","article-title":"Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues","volume":"68","author":"J M Bronstein","year":"2011","journal-title":"Arch Neurol"},{"issue":"06","key":"ref36","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/jama.2019.22360","article-title":"Diagnosis and Treatment of Parkinson Disease: A Review","volume":"323","author":"M J Armstrong","year":"2020","journal-title":"JAMA"}],"container-title":["Arquivos de Neuro-Psiquiatria"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0045-1814375.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T23:30:24Z","timestamp":1769383824000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0045-1814375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":35,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2026,1,25]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["s00451814375"],"URL":"https:\/\/doi.org\/10.1055\/s-0045-1814375","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0004-282X","1678-4227"],"issn-type":[{"value":"0004-282X","type":"print"},{"value":"1678-4227","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}